Literature DB >> 581950

Absolute bioavailability of digoxin tablets.

T Beveridge, E Nüesch, E E Ohnhaus.   

Abstract

Ten healthy male volunteers each received 0.5 mg digoxin orally and i.v. in a randomised, cross-over sequence with at least two weeks between doses. Plasma concentration and cumulative urinary excretion of digoxin were measured up to 6 and 144 h, respectively, after administration using a radioimmunoassay method. Absolute bioavailability (i.e. the percentage absorption from tablets compared to i.v. injection) was calculated by four methods: by comparing areas under plasma concentration/time curves (AUC) up to 6 h and to infinity, also by comparing cumulative urinary excretion up to 144 h (t max.) and to infinity. The mean of the two extrapolated values for the absolute bioavailability of digoxin (Sandoz) tablets is 78%.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 581950

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  9 in total

1.  Effect of Gastric Fluid Volume on the In Vitro Dissolution and In Vivo Absorption of BCS Class II Drugs: a Case Study with Nifedipine.

Authors:  Ahmed M Nader; Sara K Quinney; Hala M Fadda; David R Foster
Journal:  AAPS J       Date:  2016-04-22       Impact factor: 4.009

Review 2.  Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies.

Authors:  Mitsuo Saito; Mutsuko Hirata-Koizumi; Mariko Matsumoto; Tsutomu Urano; Ryuichi Hasegawa
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Re-examination of digoxin dosage regimen: comparison of the proposed nomograms or formulae in elderly patients.

Authors:  G Tsujimoto; T Sasaki; T Ishizaki; T Suganuma; H Hirayama
Journal:  Br J Clin Pharmacol       Date:  1982-04       Impact factor: 4.335

4.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

5.  Pharmacokinetics of the digoxin-quinidine interaction via mixed-effect modelling.

Authors:  P J Williams; J Lane; W Murray; M A Mergener; M Kamigaki
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

6.  Absorption of digoxin in severe right heart failure.

Authors:  E E Ohnhaus; S Vozeh; E Nuesch
Journal:  Eur J Clin Pharmacol       Date:  1979-03-26       Impact factor: 2.953

7.  Comparison of two different loading doses of digoxin in severe renal impairment.

Authors:  E E Ohnhaus; H R Lenzinger; R L Galeazzi
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

8.  Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers.

Authors:  Manoli Vourvahis; Wonkyung Byon; Cheng Chang; Vu Le; Annette Diehl; Daniela Graham; Sakambari Tripathy; Nancy Raha; Lina Luo; Sumathy Mathialagan; Martin Dowty; A David Rodrigues; Bimal Malhotra
Journal:  Clin Pharmacol Ther       Date:  2022-05-09       Impact factor: 6.903

9.  Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin.

Authors:  Ali A Alhadab; Ahmed Hamed Salem; Kevin J Freise
Journal:  Clin Transl Sci       Date:  2020-03-13       Impact factor: 4.689

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.